Free Trial
NASDAQ:FTRE

Fortrea Q3 2025 Earnings Report

Fortrea logo
$10.80 +0.28 (+2.66%)
Closing price 10/23/2025 04:00 PM Eastern
Extended Trading
$10.70 -0.11 (-0.97%)
As of 10/23/2025 05:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Fortrea EPS Results

Actual EPS
N/A
Consensus EPS
$0.16
Beat/Miss
N/A
One Year Ago EPS
N/A

Fortrea Revenue Results

Actual Revenue
N/A
Expected Revenue
$643.43 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Fortrea Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Wednesday, November 5, 2025
Conference Call Time
8:00AM ET

Conference Call Resources

Fortrea Earnings Headlines

Nvidia CEO Makes First Ever Tesla Announcement
While headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $25 trillion AI revolution — one that Nvidia’s CEO himself has called a “multi-trillion-dollar future industry” — and he’s uncovered a little-known stock 168 times smaller than Nvidia that could be positioned to ride this breakthrough.tc pixel
Fortrea (NASDAQ:FTRE) Raised to "Buy" at Wall Street Zen
See More Fortrea Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Fortrea? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fortrea and other key companies, straight to your email.

About Fortrea

Fortrea (NASDAQ:FTRE), Inc. is a global contract development and manufacturing organization (CDMO) that provides integrated solutions for pharmaceutical and biotechnology companies. Established as a spin-off from Thermo Fisher Scientific’s Pharma Services business in October 2023, Fortrea leverages a legacy of scientific expertise and manufacturing scale to support drug development from early-stage research through commercial production. The company’s comprehensive offerings address the complex needs of both small-molecule and biologics programs, making it a single source for clients seeking to accelerate timelines and manage costs.

Fortrea’s core services encompass analytical and formulation development, process optimization, clinical and commercial manufacturing, and packaging services. Its small-molecule capabilities include custom synthesis, active pharmaceutical ingredient (API) production, and high-potency manufacturing. On the biologics side, the company offers cell line development, microbial and mammalian cell culture, purification, viral vector production, and fill-finish operations. Complementing these laboratory and production capacities, Fortrea delivers quality assurance, regulatory support, and supply chain management to help clients navigate stringent global regulatory environments.

With its headquarters in Horsham, Pennsylvania, Fortrea operates a network of facilities across North America, Europe, and Asia, serving a diverse international client base. These strategically located sites enable the company to provide flexible manufacturing scales—from gram-scale clinical batches to multi-metric-ton commercial volumes—while ensuring continuity of supply and localized regulatory compliance. Fortrea’s global footprint supports time-sensitive project needs and offers clients access to specialized technologies and expertise in multiple regions.

Led by Chief Executive Officer James Mullen, Fortrea’s leadership team draws on decades of experience in pharmaceutical development and manufacturing. The company’s executive management combines technical know-how with a customer-focused approach, aiming to foster long-term partnerships and drive innovation. As a newly independent entity, Fortrea continues to invest in capacity expansions and technology upgrades to meet the evolving demands of the life sciences industry.

View Fortrea Profile

More Earnings Resources from MarketBeat